MA49690A - Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations - Google Patents

Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations

Info

Publication number
MA49690A
MA49690A MA049690A MA49690A MA49690A MA 49690 A MA49690 A MA 49690A MA 049690 A MA049690 A MA 049690A MA 49690 A MA49690 A MA 49690A MA 49690 A MA49690 A MA 49690A
Authority
MA
Morocco
Prior art keywords
tgf
beta
specific inhibitors
ltbp complex
ltbp
Prior art date
Application number
MA049690A
Other languages
English (en)
Inventor
Gregory J Carven
Abhishek Datta
Christopher Littlefield
Thomas Schurpf
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA49690A publication Critical patent/MA49690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA049690A 2017-07-28 2018-07-27 Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations MA49690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538476P 2017-07-28 2017-07-28
US201762585148P 2017-11-13 2017-11-13

Publications (1)

Publication Number Publication Date
MA49690A true MA49690A (fr) 2021-05-19

Family

ID=63245030

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049690A MA49690A (fr) 2017-07-28 2018-07-27 Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations

Country Status (5)

Country Link
US (1) US20200231682A1 (fr)
EP (1) EP3658583A1 (fr)
CA (1) CA3071427A1 (fr)
MA (1) MA49690A (fr)
WO (1) WO2019023661A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075090A1 (fr) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
EP3820896A1 (fr) 2018-07-11 2021-05-19 Scholar Rock, Inc. INHIBITEURS DE TGFbeta1 ET LEUR UTILISATION
TW202005981A (zh) 2018-07-11 2020-02-01 美商供石公司 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
MA52165A (fr) 2018-07-11 2021-06-02 Scholar Rock Inc Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
PE20220279A1 (es) * 2019-01-30 2022-02-25 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
TW202142571A (zh) 2019-08-28 2021-11-16 日商中外製藥股份有限公司 跨物種抗潛伏性TGF-β1抗體及使用方法
AU2021205433A1 (en) 2020-01-11 2022-08-18 Scholar Rock, Inc. Tgfß inhibitors and use thereof
EP4087659A2 (fr) 2020-01-11 2022-11-16 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
WO2021195088A1 (fr) * 2020-03-23 2021-09-30 The Regents Of The University Of Colorado, A Body Corporate INHIBITEURS DE TGF-Bβ1 POUR PRÉVENIR ET TRAITER SARS-COV-2
EP4348260A2 (fr) 2021-06-03 2024-04-10 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2105300C (fr) 1991-03-01 2008-12-23 Robert C. Ladner Procede pour le developpement de mini-proteines fixatrices
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
WO2015171691A2 (fr) * 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
CA3055555A1 (fr) 2016-03-11 2017-09-14 Scholar Rock, Inc. Immunoglobulines se liant a tgfb1 et leur utilisation
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof

Also Published As

Publication number Publication date
US20200231682A1 (en) 2020-07-23
CA3071427A1 (fr) 2019-01-31
WO2019023661A1 (fr) 2019-01-31
EP3658583A1 (fr) 2020-06-03

Similar Documents

Publication Publication Date Title
MA49690A (fr) Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
MA50618A (fr) Polyrhérapies et leurs utilisations
MA50502A (fr) Adénovirus et utilisations associées
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
DK3681884T3 (da) Rad51-inhibitorer
DK3287810T3 (da) Vindmålingsindretning og lidarindretning
MA50465A (fr) Compositions de peptides tau phosphorylés et leurs utilisations
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
MA46945A (fr) Exopolysaccharides et leurs utilisations
MA54845A (fr) Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA49124A (fr) Panneau et revêtement
MA49905A (fr) Polyesteramines et polyesterquats
MA44968A (fr) Esters d'oxaborole et leurs utilisations
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
MA46901A (fr) Agents psychotropes et leurs utilisations
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
MA45411A (fr) Compositions antimalariques et leurs utilisations